Co-Diagnostics Q3 2026 earnings
Revenue more than doubled YoY, but operating losses widened due to higher costs and a tax benefit reversal.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $282.9M | +94.6% | +70.2% | Ex. 99.1, income statement |
| EPS (GAAP) | -$1.01 | +78.4% | +30.7% | Ex. 99.1, income statement |
| Net income | -$6.3M | +7.0% | +0.4% | Ex. 99.1, income statement |
| Adj. EBITDA | -$2.0M | +94.6% | +70.2% | Ex. 99.1, income statement |
| Adj. EBITDA margin | -0.7% | +1.3 pp | +0.5 pp | Ex. 99.1, income statement |
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin -7.2% (prior -22.4%, change +15.2 pp)
- Operating expenses $6.2M (+12.5% YoY)
- One-offs in the quarter Income tax provision $500 (vs $1.2M benefit YoY); Gain on remeasurement of acquisition contingencies $60.4M; Loss on equity method investment in joint ventures $100.0M
- Effective tax rate 0.0% (prior -16.4%, year-to-date 0.0%)
- Non-GAAP bridge Depreciation, amortization, interest, stock-based compensation, contingent consideration, realized gains/losses on investments
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Product revenue | $282.9M | $166.1M | $145.4M | +70.2% QoQ, +94.6% YoY |
| Weighted average shares outstanding | 6.3M | 4.3M | 1.3M | +46.5% QoQ, +397.6% YoY |
Guidance
not stated in the 8-K
What drove it
- Revenue story Product revenue increased 94.6% YoY to $282.9M, driven by a 70.2% QoQ increase.
- EPS story EPS improved from -$4.66 to -$1.01 YoY due to higher revenue and a tax benefit reversal.
- One-off check Income tax provision $500 (vs $1.2M benefit YoY); Gain on remeasurement of acquisition contingencies $60.4M; Loss on equity method investment in joint ventures $100.0M
The good
- Revenue more than doubled YoY (+94.6%)
- Adj. EBITDA margin improved by 1.3 pp YoY
The bad
- Operating expenses increased 12.5% YoY
- Cost of revenue ($303.3M) exceeded revenue ($282.9M)
- Loss on equity method investment in joint ventures ($100.0M)
The ugly
- none
Open questions
- What caused the $100.0M loss on equity method investment in joint ventures?
- What caused the $60.4M gain on remeasurement of acquisition contingencies?
- Why did the company issue 3.2M additional shares in Q3 (from 4.3M to 6.3M outstanding)?
Full release
Co-Diagnostics (CODX) earnings release, November 10, 2026
Exhibit
99.1
Co-Diagnostics
Reports Third Quarter 2026 Financial Results
Two
Regulatory Submissions Under Review in India and the U.S.
Third
Quarter Operating Expenses Down 12% Year Over Year
Platform
Capabilities Expanding with ReadyGo Collaboration, India Connectivity and Vector Smart Growth
SALT
LAKE CITY, November 10, 2026 – Co-Diagnostics, Inc.
(Nasdaq: CODX)
(“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the third quarter ended September 30, 2026.
Third
Quarter 2026 Business Highlights:
“The third quarter was a period of significant regulatory and operational progress for Co-Diagnostics,” said Dwight Egan, Chief Executive
Officer of Co-Diagnostics. “CoSara completed its clinical performance study for our point-of-care tuberculosis test and submitted it to India’s Central Drugs Standard Control Organization (CDSCO), and together with our August FDA 510(k) submission for the Flu
A/B & RSV test, we now have two regulatory submissions under review in two important markets for our platform.
We also launched our cloud and mobile infrastructure in India, began evaluating blood-based testing with ReadyGo, and completed the first international deployment of Vector Smart. With our submissions in India and the U.S. under review, our focus is on supporting those reviews, advancing our feasibility work with ReadyGo and continuing to grow Vector Smart.”
Recent
Developments:
Third
Quarter 2026 Financial Results:
Conference
Call and Webcast:
Co-Diagnostics will host a conference call and webcast at 4:30 p.m. ET today to review its third quarter 2026 results. The conference call and webcast will be available via:
Webcast: ir.co-dx.com on the
Events & Webcasts page, or accessible directly here
Conference
Call: 1-888-880-3330 (Toll Free) or 1-646-357-8766 (Toll)
The call will be recorded and later made available on the Company’s website.
*The
Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) is subject to review or authorization by applicable regulatory authorities in the jurisdictions in which clearance or approval is sought, including the US FDA, and is not yet available for sale.
About
Co-Diagnostics, Inc.:
Co-Diagnostics,
Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.
The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules
(DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform
(subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
Non-GAAP
Financial Measures:
This press release contains adjusted EBITDA, a non-GAAP measure defined as net income (loss) adjusted for depreciation, amortization, income tax (benefit) expense, net interest (income) expense, stock-based compensation, change in fair value of contingent consideration, and realized gain (loss) on investments. The Company believes that adjusted EBITDA provides useful information to management and investors relating to its results of operations. The Company’s management uses this non-GAAP measure to compare the Company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.
Management does not consider the non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of the non-GAAP financial measure is that it excludes significant expenses that are required by GAAP to be recorded in the Company’s financial statements. In order to compensate for these limitations, management presents the non-GAAP financial measure together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of the net income, the most comparable
GAAP financial measure to adjusted EBITDA, is included at the end of this release. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business.
Forward-Looking
Statements:
Financial statements
Income Statement
Three Months Ended September 30, — (Unaudited)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | |
|---|---|---|
| Product revenue | 282,881 | 145,380 |
| Total revenue | 282,881 | 145,380 |
| Cost of revenue | 303,344 | 26,285 |
| Gross profit | -20,463 | 119,095 |
| Operating expenses | ||
| Sales and marketing | 579,902 | 568,937 |
| General and administrative | 1,871,838 | 1,815,945 |
| Research and development | 3,574,784 | 4,480,678 |
| Depreciation and amortization | 222,363 | 267,383 |
| Total operating expenses | 6,248,887 | 7,132,943 |
| Loss from operations | -6,269,350 | -7,013,848 |
| Other income (expense), net | ||
| Interest income, net | 3,123 | 13,194 |
| Realized gain on investments | 41,542 | |
| Gain (loss) on disposition of assets | 4,000 | |
| Gain (loss) on remeasurement of acquisition contingencies | 60,355 | -42,345 |
| Loss on equity method investment in joint ventures | -100,036 | -55,959 |
| Total other income (expense), net | -36,558 | -39,568 |
| Loss before income taxes | -6,305,908 | -7,053,416 |
| Income tax provision (benefit) | 500 | -1,166,593 |
| Net loss | -6,306,408 | -5,886,823 |
| Other comprehensive loss | ||
| Change in net unrealized gains on marketable securities, net of tax | -39,180 | |
| Total other comprehensive loss | $- | -39,180 |
| Comprehensive loss | -6,306,408 | -5,926,003 |
| Loss per common share: | ||
| Basic and Diluted | -1.01 | -4.66 |
| Weighted average shares outstanding: | ||
| Basic and Diluted | 6,272,635 | 1,263,031 |
Balance Sheet
September 30, 2026 — (Unaudited)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | 714,803 | 11,884,607 |
| Accounts receivable, net | 51,828 | 190,375 |
| Inventory, net | 672,950 | 992,397 |
| Income taxes receivable | 44,559 | |
| Prepaid expenses and other current assets | 498,517 | 581,527 |
| Total current assets | 1,938,098 | 13,693,465 |
| Property and equipment, net | 1,767,749 | 2,272,098 |
| Operating lease right-of-use asset | 1,531,986 | 1,207,453 |
| Intangible assets, net | 7,219,000 | 7,219,000 |
| Investment in joint ventures | 335,015 | 350,569 |
| Total assets | 12,791,848 | 24,742,585 |
| Current liabilities | ||
| Accounts payable | 937,294 | 1,878,225 |
| Accrued expenses | 850,200 | 865,301 |
| Operating lease liability, current | 709,754 | 662,258 |
| Contingent consideration liabilities, current | 12,572 | 119,036 |
| Deferred revenue | 2,000 | 14,800 |
| Total current liabilities | 2,511,820 | 3,539,620 |
| Long-term liabilities | ||
| Operating lease liability | 854,749 | 574,301 |
| Total long-term liabilities | 854,749 | 574,301 |
| Total liabilities | 3,366,569 | 4,113,921 |
| Stockholders’ equity | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 7,450,224 shares issued and 7,288,601 shares outstanding as of September 30, 2026 and 2,256,654 shares issued and 2,095,031 shares outstanding as of December 31, 2025 | 72,893 | 67,700 |
| Treasury stock, at cost; 161,623 shares held as of September 30, 2026 and December 31, 2025, respectively | -15,575,795 | -15,575,795 |
| Additional paid-in capital | 127,031,952 | 116,510,298 |
| Accumulated deficit | -102,103,771 | -80,373,539 |
| Total stockholders’ equity | 9,425,279 | 20,628,664 |
| Total liabilities and stockholders’ equity | 12,791,848 | 24,742,585 |
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include, but are not limited to, statements regarding: (i) the continued development, clinical evaluation, regulatory submission, clearance, authorization, and commercialization... (truncated) and regulatory reviews, including the anticipated timing of CDSCO clearance and the commencement of commercial sales in India; (iii) the Company’s ability to develop, scale, and commercialize its manufacturing capabilities, including through CoSara and CoMira and other third parties;
(iv) anticipated market opportunities and international expansion initiatives; (v) the expected capabilities, differentiation, and adoption of the Company’s platform technologies; and (vi) the Company’s strategic, operational, and growth initiatives generally.
Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. These risks and uncertainties include, among others, risks relating to the timing and outcome of FDA and other regulatory review processes; the possibility that clinical or analytical data may not support regulatory clearance, authorization or commercialization; the Company’s ability to successfully complete product development, manufacturing scale-up and commercialization activities; market acceptance and adoption of the Company’s products and technologies; the Company’s dependence on joint ventures, distributors, manufacturers and other third parties; risks associated with conducting business and obtaining regulatory approvals in international markets; the Company’s ability to obtain additional capital when needed, maintain sufficient liquidity to execute its business plans and continue as a going concern; and competitive and technological developments. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any regulatory submission, authorization, commercialization milestone, manufacturing initiative, strategic collaboration, or market opportunity will occur on the timelines anticipated by the Company, or at all, due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission
(SEC) on March 31, 2026, and in our other filings with the SEC. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by applicable law.
Investor
Contact:
Valter
Pinto, Managing Director
KCSA
Strategic Communications
+1
212.896.1254
CODX@KCSA.com
Media
Contact:
Jennifer
Webb
ColtrinMethod
PR jcoltrin@coltrinmethodpr.com
CO-DIAGNOSTICS,
INC. AND SUBSIDIARIES